The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer

Mori, G., & Pasca, M. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031312 · Cited by 28

Immune Checkpoints in Endometriosis—A New Insight in the Pathogenesis

Suszczyk, D., Skiba, W., Pawłowska, A., Dymanowska-Dyjak, I., Włodarczyk, K., Paduch, R., & Wertel, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116266 · Cited by 26

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 27

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade

Ganbaatar, O., Konnai, S., Okagawa, T., Nojima, Y., Maekawa, N., Minato, E., Kobayashi, A., Andõ, R., Sasaki, N., Miyakoshi, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234218 · Cited by 23

Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity

Silva-Pilipich, N., Martišová, E., Ballesteros-Briones, M. C., Hervás‐Stubbs, S., Casares, N., González‐Sapienza, G., Smerdou, C., & Vanrell, L. (2020) · Biomedicines · doi:10.3390/biomedicines8120562 · Cited by 23

18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects

Prigent, K., & Aide, N. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.006 · Cited by 24

Biological bases of cancer immunotherapy

Carazas, M. M. G., Pinto, J. A., & Casado, F. L. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.5 · Cited by 23

Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction

Qin, Q., Fan, L., Zeng, X., Zheng, D., Wang, H., Li, M., Jiang, Y., Wang, H., Liu, H., Liang, S., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03250-z · Cited by 24

Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary

Sue-A-Quan, R., Patel, P. G., Shakfa, N. E., Nyi, M.-P. N., Afriyie-Asante, A., Kang, E. Y., Köbel, M., & Koti, M. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.010 · Cited by 22

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

Versteven, M., den Bergh, J. M. J. V., Broos, K., Fujiki, F., Campillo-Davó, D., Reu, H. D., Morimoto, S., Lecocq, Q., Keyaerts, M., Berneman, Z. N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25591 · Cited by 22

H3K4me3 mediates the NF-κB p50 homodimer binding to thepdcd1promoter to activate PD-1 transcription in T cells

Redd, P. S., Lu, C., Klement, J. D., Ibrahim, M. L., Zhou, G., Kumai, T., Celis, E., & Liu, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1483302 · Cited by 21

HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings

Boschert, V., Teusch, J., Aljasem, A., Schmucker, P., Klenk, N., Straub, A., Bittrich, M., Seher, A., Linz, C., Müller-Richter, U. D. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228770 · Cited by 22

A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies

Silva-Pilipich, N., Smerdou, C., & Vanrell, L. (2021) · Microorganisms · doi:10.3390/microorganisms9091956 · Cited by 22

Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease

Forster, S., & Radpour, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941437 · Cited by 21

Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules

D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21

Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer

Pinto, J. A., Raez, L. E., Oliveres, H., & Rolfo, C. D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1610380 · Cited by 22

Opportunities and challenges for the development of covalent chemical immunomodulators

Backus, K. M., Cao, J. X., & Maddox, S. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.050 · Cited by 21

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms

Almeida, S. D., Regimbeau, M., Jégo, G., Garrido, C., Girodon, F., & Hermetet, F. (2020) · Cancers · doi:10.3390/cancers12092592 · Cited by 21

Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors

Re, M. D., van Schaik, R. H. N., Fogli, S., Mathijssen, R. H. J., Cucchiara, F., Capuano, A., Scavone, C., Jenster, G. W., & Danesi, R. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188463 · Cited by 20

CD8 + T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis

Kelkar, M. G., Bargir, U. A., Yadav, R. M., Gupta, M., Dalvi, A. D., Jodhawat, N., Shinde, S., & Madkaikar, M. R. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01109-0 · Cited by 20

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review

Adamczyk, M., & Krasowska, D. (2021) · Advances in Dermatology and Allergology · doi:10.5114/ada.2021.112274 · Cited by 20

Exosomal microRNAs shuttling between tumor cells and macrophages: cellular interactions and novel therapeutic strategies

Xu, W., Wang, D., Zhao, Z., Zhang, H.-D., Yang, S., Zhang, Q., Li, L., & Zhang, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02594-y · Cited by 21

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy

Lak, S., Janelle, V., Djedid, A., Boudreau, G., Brasey, A., Lisi, V., Smaani, A., Carli, C., Busque, L., Lavallée, V., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.016 · Cited by 19

MDM2 inhibitors in cancer immunotherapy: Current status and perspective

Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 20

Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status

Holmes, M., Mahar, A. M., Lum, T., Kao, S., & Cooper, W. A. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206709 · Cited by 20

Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials

Plavc, G., & Strojan, P. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0060 · Cited by 20

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway

Liu, Q., & Li, C. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.204113 · Cited by 20

PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients

Schulze, A. B., & Schmidt, L. H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.118 · Cited by 20

Immune checkpoint blockade in cancer: current insights and future horizons

Saman, H. T., Makni‐Maalej, K., El-Ella, D. M. A., Al-Tamimi, M. Y., AbuHaweeleh, M. N., Abuhayeh, N., Ismail, M. A., Prabhu, K. S., Fernandes, Q., Jabi, T., et al. (2026) · Discover Oncology · doi:10.1007/s12672-025-04361-7 · Cited by 20

Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Xu, Y., Du, H., Guo, W., Liu, B., Yan, W., Zhang, C., Qin, L., Huang, J., Wang, H., Wu, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02362 · Cited by 19

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy

Lai, K.-C., Chen, Y., Hung, Y., Chiang, N.-J., Chen, M., & Chen, S. (2024) · Hepatology International · doi:10.1007/s12072-024-10728-9 · Cited by 20

Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils

Li, C., Chen, C., Kang, X., Zhang, X., Sun, S., Guo, F., Wang, Q., Kou, X., Bai, W., & Zhao, A. (2020) · Human Reproduction · doi:10.1093/humrep/deaa217 · Cited by 19

The expression of selected molecular markers of immune tolerance in psoriatic patients

Bartosińska, J., Purkot, J., Kowal, M., Michalak-Stoma, A., Krasowska, D., Chodorowska, G., & Giannopoulos, K. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/78020 · Cited by 18

Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects

Xie, S., Hou, X., Yang, W., Shi, W., Yang, X., Duan, S., Mo, F., Liu, A., Wang, W., & Lü, X. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s317220 · Cited by 18

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

Xie, W., Medeiros, L. J., Li, S., Tang, G., Fan, G., & Xu, J. (2022) · Biomedicines · doi:10.3390/biomedicines10071587 · Cited by 18

Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal

Lopes-Brás, R., Lopéz‐Presa, D., Esperança‐Martins, M., Melo-Alvim, C., Gallego-Paez, L. M., Costa, L., & Fernandes, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214227 · Cited by 19

Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

Wang, X., Ling, X., Wang, C., Zhang, J., Yang, Y., Jiang, H., Xin, Y., Zhang, L., Liang, H., Fang, C., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03354-7 · Cited by 18

Inflammatory Network of Liver Fibrosis and How It Can Be Targeted Therapeutically

Lowe, K., Tanase, C. E., Maghami, S., Fisher, L. E., & Ghaemmaghami, A. M. (2023) · Immuno · doi:10.3390/immuno3040023 · Cited by 19

Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells

Kim, B. G., Kim, B. R., Kim, D. Y., Kim, W. Y., Kang, S., Lee, S. I., & Oh, S. C. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0902 · Cited by 19

TcR-α recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers

Mai, A. T., Tong, W. L., Tu, Y. N., & Blanck, G. (2018) · International Immunology · doi:10.1093/intimm/dxx074 · Cited by 18

Targeting PD-1 in cancer: Biological insights with a focus on breast cancer

Solinas, C., Aiello, M. M., Silva, P. D., Gu‐Trantien, C., Migliori, E., & Willard-Gallo, K. E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.011 · Cited by 18

Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study

Grywalska, E., Pasiarski, M., Sosnowska‐Pasiarska, B., Macek, P., Rolińska, A., Samardakiewicz, M., Ludian, J., Góźdź, S. S., & Roliński, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s212069 · Cited by 18

Cell-mediated immune resistance in cancer

Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 20

Profiles of PD‐1, PD‐L1, PD‐L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival

Liu, J., Li, H. R., Sun, L. L., Yuan, Y., & Xing, C. (2020) · BioMed Research International · doi:10.1155/2020/2496582 · Cited by 18

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Li, M., Zhang, X., Bai, X., & Liang, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862154 · Cited by 18

PDCD5 regulates cell proliferation, cell cycle progression and apoptosi

Li, P., Fei, H., Wang, L., Xu, H., Zhang, H., & Zheng, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7401 · Cited by 18

Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity

Tsuda, S., Carreras, J., Kikuti, Y. Y., Nakae, H., Dekiden‐Monma, M., Imai, J., Tsuruya, K., Nakamura, J., Tsukune, Y., Uchida, T., et al. (2019) · Pathology International · doi:10.1111/pin.12794 · Cited by 18

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma

Huang, S., Nong, L., Li, L., Zheng, Y., Wang, W., Liu, J., Li, D., Li, X., Wang, Y., Zhang, B., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2316 · Cited by 18

Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions

Wang, B., Xiang, Y., Liu, X., Pan, X., Peng, L., & Ma, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582887 · Cited by 18

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

Pi, C., Jing, P., Li, B., Feng, Y., Xu, L., Xie, K., Huang, T., Xu, X., Gu, H., & Fang, J. (2022) · Cancers · doi:10.3390/cancers14174134 · Cited by 17

Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine

Niebergall‐Roth, E., Frank, N. Y., Ganss, C., Frank, M. H., & Kluth, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010066 · Cited by 20

The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity

Zhang, X., Gao, Y., Yang, B., Ma, S., Zuo, W., & Wei, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109895 · Cited by 18

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy

Ohkuma, R., Fujimoto, Y., Ieguchi, K., Onishi, N., Watanabe, M., Takayanagi, D., Goshima, T., Horiike, A., Hamada, K., Ariizumi, H., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.13967 · Cited by 18

Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response

Hashemi, M., Daneii, P., Zandieh, M. A., Raesi, R., Zahmatkesh, N., Bayat, M., Abuelrub, A., Koohpar, Z. K., Aref, A. R., Zarrabi, A., et al. (2023) · Non-coding RNA Research · doi:10.1016/j.ncrna.2023.11.005 · Cited by 18

Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis

Atkins, P., & Thompson, D. M. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.005 · Cited by 17

Nivolumab treatment for metastatic thymic epithelial tumors

Ak, N., & Aydıner, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220968150 · Cited by 17

Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis

Fallon, E. A., Chun, T. T., Young, W. A., Gray, C. C., Ayala, A., & Heffernan, D. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01469 · Cited by 17

Should basic science matter to clinicians?

Filewod, N. C. J., Batt, J. A. E., Kapùs, A., Szászi, K., Fairn, G. D., Slutsky, A. S., & Lee, W. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30199-5 · Cited by 17

TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients

Dadiani, M., Necula, D., Kahana‐Edwin, S., Oren, N., Baram, T., Marin, I., Morzaev‐Sulzbach, D., Pavlovski, A., Balint‐Lahat, N., Anafi, L., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02549-0 · Cited by 16

PD-1: A New Candidate Target for Analgesic Peptide Design

Zhao, L., Ma, Y., Song, X., Wu, Y., Jin, P., & Chen, G. (2023) · Journal of Pain · doi:10.1016/j.jpain.2023.02.002 · Cited by 17

Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer

Yan, X.-D., Bai, L., Qi, P., Lv, J., Song, X., & Zhang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411387 · Cited by 16

Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

Sagrero‐Fabela, N., Chávez-Mireles, R., Salazar‐Camarena, D. C., & Palafox‐Sánchez, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147726 · Cited by 21

The unexpected PD-L1 suppression function of celery-derived extracellular vesicles improves lung cancer chemotherapy efficacy

Lu, X. B., Yu, Z., Wang, J., Tian, A., Wu, T., Cheng, Y., Han, Q., Li, F., & Xia, W. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.75 · Cited by 16

Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis

Abdelhafeez, A. A. M., Shohdy, K. S., & Ibrahim, W. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1714053 · Cited by 16

Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes

Cocco, C., Morandi, F., & Airoldi, I. (2021) · Cells · doi:10.3390/cells10040927 · Cited by 18

Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response

Olmos, M., Glajzer, J., Büntemeyer, T.-O., Frohwitter, G., Ries, J., Eckstein, M., Hecht, M., Lutz, R., Kesting, M. R., & Weber, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720951 · Cited by 16

Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma

McShane, R., Arya, S., Stewart, A. J., Caie, P. D., & Bates, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188598 · Cited by 16

Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis

Franz, L., Alessandrini, L., Ottaviano, G., Carlo, R. D., Fasanaro, E., Ramacciotti, G., Contro, G., & Marioni, G. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153120 · Cited by 16

Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer

Marinelli, O., Annibali, D., Morelli, M. B., Zeppa, L., Tuyaerts, S., Aguzzi, C., Amantini, C., Maggi, F., Ferretti, B., Santoni, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.538064 · Cited by 16

Advances in immunology of obstructive sleep apnea: mechanistic insights, clinical impact, and therapeutic perspectives

Dong, N., & Yue, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654450 · Cited by 18

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma

Zhou, X., Hu, Y., Sun, H., Chen, R., Huang, G., & Liu, J. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06251-y · Cited by 15

The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function

Balasko, A. L., Kowatsch, M. M., Graydon, C. G., Lajoie, J., & Fowke, K. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-36468-8 · Cited by 15

Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction

Zhang, F., Yu, Q., Wu, C., Sun, S., Wang, Y., Wang, Y., Zejie, C., Zhang, H., Xiong, X., Awadasseid, A., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117867 · Cited by 16

Therapeutic implications for the PD-1 axis in cerebrovascular injury

Feghali, J., & Jackson, C. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00459 · Cited by 15

Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility

Shindiapina, P., & Alinari, L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761777 · Cited by 15

Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report

Yu, Q., & Wang, W. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i3.624 · Cited by 15

Comprehensive co‑expression analysis reveals TMC8 as a prognostic immune‑associated gene in head and neck squamous cancer

Lin, B., Wang, S., Yao, Y., Shen, Y., & Yang, H. (2021) · Oncology Letters · doi:10.3892/ol.2021.12759 · Cited by 15

Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis

Jin, Y., Wei, J., Weng, Y., Feng, J., Xu, Z., Wang, P., Cui, X. J., Chen, X., Wang, J., & Peng, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.732814 · Cited by 16

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma

Chan, L. L., & Chan, S. L. (2022) · Cancers · doi:10.3390/cancers14061526 · Cited by 16

Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs

Yang, H., Yang, C., Wu, C., Wang, L.-J., & Lu, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133162 · Cited by 15

Interleukin (IL)-7 Signaling in the Tumor Microenvironment

Bednarz-Misa, I. S., Bromke, M. A., & Krzystek‐Korpacka, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55617-4_2 · Cited by 15

Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review

Luttwak, E., Gurevich‐Shapiro, A., Azem, F., Lishner, M., Klieger, C., Herishanu, Y., Perry, C., & Avivi, I. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100831 · Cited by 14

Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments

Patel, A. R., Patel, D. N., Tu, Y. N., Yeagley, M. G., Chobrutskiy, A., Chobrutskiy, B. I., & Blanck, G. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2070546 · Cited by 14

Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions

Dougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 15

Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China

Qu, W., Wang, F., Qin, S., Sun, Y., & Huang, C. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241242607 · Cited by 15

Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management

Czaja, A. J. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5072-x · Cited by 14

Differentially Tolerized Mouse Antigen Presenting Cells Share a Common miRNA Signature Including Enhanced mmu-miR-223-3p Expression Which Is Sufficient to Imprint a Protolerogenic State

Bros, M., Youns, M., Kollek, V., Buchmüller, D., Bollmann, F., Seo, E., Schupp, J., Montermann, E., Usanova, S., Kleinert, H., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00915 · Cited by 14

Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management

Williams, S. G., Mollaeian, A., Katz, J. D., & Gupta, S. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1804362 · Cited by 14

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients

Gao, G., Zhang, X.-D., Qu, H., Yao, B., Zhou, Y., Xiang, J., Chen, C., Hou, T., Chen, K., & Xu, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-853 · Cited by 14

Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer

Nero, C., Romito, I., Spadola, S., Romito, A., Turco, L. C., Cosentino, F., Ninno, M. D., Catena, U., Nardone, A. D. C., Moroni, R., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.08.032 · Cited by 14

Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression

Xu, X., Xie, K., Li, B., Xu, L., Huang, L., Feng, Y., Pi, C., Zhang, J., Huang, T., Jiang, M., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108199 · Cited by 14

Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity

Saadi, W., Fatmi, A., Pallardó, F. V., García‐Giménez, J. L., & Mena, S. (2022) · Cancers · doi:10.3390/cancers15010184 · Cited by 15

Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors

Ghosh, A., Politikos, I., & Perales, M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000408 · Cited by 14

Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis

Czaja, A. J. (2019) · Autoimmunity · doi:10.1080/08916934.2019.1641200 · Cited by 15

Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD−L1

Jouini, N., Cardinale, J., & Mindt, T. L. (2022) · ChemMedChem · doi:10.1002/cmdc.202200091 · Cited by 13

Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model

Kong, P., Yang, H., Tong, Q., Dong, X., Yi, M.-A., & Yan, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04949-y · Cited by 12

ZIF-8-Modified Multifunctional Hydrogel Loading siRNA and DOX for Postoperative Therapy of Maxillofacial Osteosarcoma and Bone Repair

Zhou, J., Lin, G., Fu, X., Qiu, S., Zhang, Y., Chen, X., Liu, Y., Wan, X., Li, Z., Li, Y., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c21331 · Cited by 17

PD‐L1 overexpression conveys tolerance of mesenchymal stem cell‐derived cardiomyocyte‐like cells in an allogeneic mouse model

Mardomi, A., Khodashenas, S., Rahbarghazi‬, R., Mohammadi, N., Khorashadizadeh, M., Ranjbaran, H., Hossein‐Nataj, H., Jafari, N., Hasani, B., & Abediankenari, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30299 · Cited by 13

Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer

AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154338 · Cited by 13

A Systematic Study of the Degeneration of Articular Cartilage in Bovine Joints.

Bennett, G. A., & Bauer, W. (1931) · Europe PMC (PubMed Central) · Cited by 13

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 190

The role of the PD‐1 pathway in autoimmunity and peripheral tolerance

Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 366

Role of PD-1 in Regulating T-Cell Immunity

Jin, H., Ahmed, R., & Okazaki, T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_116 · Cited by 310

The PD‐1 pathway in tolerance and autoimmunity

Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378